DRAK2 antibody (Internal Region)

Catalog No. ABIN499168

Product Details anti-DRAK2 Antibody

Target: DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))

Binding Specificity: Internal Region

Reactivity: Human, Dog

Host: Goat

Clonality: Polyclonal

Conjugate: This DRAK2 antibody is un-conjugated

Application: Western Blotting (WB)

Sequence: C-HSVRSSEDKT SK

Specificity: This antibody detects STK17B / DRAK2 (Internal).

Cross-Reactivity (Details): Species reactivity (expected):DogSpecies reactivity (tested):Human

Purification: Ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide

Immunogen: Peptide from the internal region of the protein sequence according to NP_004217.1

Application Details

Application Notes: Peptide ELISA: antibody detection limit dilution 1: 32000. Western blot: 1-3 μg/mL. Approx 45 kDa band observed in lysates of cell line MOLT4(calculated MW of 42.5 kDa according to NP_004217.1).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Store at 2 - 8 °C up to one week or (in aliquots) at -20 °C for longer.

Target Details for DRAK2

Target: DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))

Alternative Name: STK17B / DRAK2 (STK17B Products)

Synonyms: zgc:65989 antibody, STK17B antibody, DRAK2 antibody, Drak2 antibody, 3110009A03Rik antibody, AI120141 antibody, serine/threonine kinase 17b (apoptosis-inducing) antibody, serine/threonine kinase 17b antibody, stk17b antibody, STK17B antibody, Stk17b antibody

Background: Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase related apoptosis inducing protein kinases). DRAKs contain an N terminal kinase domain and a C terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues. Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP,are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases) (1). DRAKs contain anN-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.Synonyms: DAP kinase-related apoptosis-inducing protein kinase 2, Serine/threonine-protein kinase 17B

Gene ID: 9262

NCBI Accession: NP_004217

UniProt: O94768